Evaluation of treatment response with PERCIST in follicular lymphoma receiving rituximab single-agent immunotherapy

被引：0
|
作者：
Tatsumi, Mitsuaki [1 ]
Watabe, Tadashi [1 ]
Kato, Hiroki [1 ]
Imaizumi, Masao [1 ]
Shimosegawa, Eku [1 ]
Hatazawa, Jun [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Suita, Osaka, Japan
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1364
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dramatic response to single-agent rituximab in a patient with intravascular lymphoma
    Vrindavanam, Nandagopal
    Hamadani, Mehdi
    Steele, Barbara
    Awan, Farrukh
    Suster, Saul
    Benson, Don M., Jr.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (12) : 1120 - 1121
  • [2] Intravascular lymphoma: a role for single-agent rituximab
    Bazhenova, L
    Higginbottom, P
    Mason, J
    LEUKEMIA & LYMPHOMA, 2006, 47 (02) : 337 - 341
  • [3] Rituximab in indolent lymphoma:: The single-agent pivotal trial
    McLaughlin, P
    Hagemeister, FB
    Grillo-López, AJ
    SEMINARS IN ONCOLOGY, 1999, 26 (05) : 79 - 87
  • [4] The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma
    Laoruangroj, Chonlada
    Atherton, Pamela J.
    Wiseman, Gregory A.
    Ansell, Stephen
    Feldman, Andrew L.
    Schumacher, Peyton
    Witzig, Thomas E.
    LEUKEMIA & LYMPHOMA, 2024, 65 (03) : 333 - 338
  • [5] Successful response to rituximab as a single agent in bulky disease follicular lymphoma.
    Ferrari, D
    Girmenia, G
    Brunati, S
    Rosato, E
    Montillo, M
    BLOOD, 2002, 100 (11) : 310B - 310B
  • [6] Complete clinical response with single-agent high dose Rituximab in mantle cell lymphoma.
    Jain, D
    Dutcher, JP
    Wiernik, PH
    BLOOD, 2003, 102 (11) : 305B - 305B
  • [7] SINGLE AGENT RITUXIMAB IS A VALID OPTION FOR FIRST-LINE TREATMENT IN FOLLICULAR LYMPHOMA
    Ghielmini, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 81 - 81
  • [8] Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98
    Martinelli, Giovanni
    Schmitz, Shu-Fang Hsu
    Utiger, Urs
    Cerny, Thomas
    Hess, Urs
    Bassi, Simona
    Okkinga, Emmie
    Stupp, Roger
    Stahel, Rolf
    Heizmann, Marc
    Vorobiof, Daniel
    Lohri, Andreas
    Dietrich, Pierre-Yves
    Zucca, Emanuele
    Ghielmini, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) : 4480 - 4484
  • [9] Has Single-Agent Rituximab Replaced Watch-and-Wait for a Patient With Asymptomatic Low-Grade Follicular Lymphoma?
    Lowry, Lisa
    Ardeshna, Kirit M.
    CANCER JOURNAL, 2012, 18 (05): : 390 - 395
  • [10] Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma
    Grzywacz, Bartosz
    Erbe, Amy K.
    Wang, Wei
    Ranheim, Erik A.
    Hank, Jacquelyn A.
    Kim, KyungMann
    Carmichael, Lakeesha
    Seo, Songwon
    Mendonca, Eneida A.
    Song, Yiqiang
    Hong, Fangxin
    Gascoyne, Randy D.
    Paietta, Elisabeth
    Horning, Sandra J.
    Kahl, Brad S.
    Sondel, Paul M.
    BLOOD, 2013, 122 (21)
12345